论文部分内容阅读
美罗华(R ituxim ab)是第一个获准用于治疗人类肿瘤的单抗产品,于1997年11月获FDA批准。上市至今,国外已进行了多项关于美罗华单用,与干扰素或其它化疗药物联用的临床研究,取得了令人鼓舞的结果。其突出的作用体现在大大提高了复发或难治性的CD20阳性B细胞淋巴瘤的缓解率和生存
Rituxab is the first monoclonal antibody approved for the treatment of human tumors and was approved by the FDA in November 1997. Since the listing, a number of clinical studies abroad have been conducted on rituximab in combination with interferon or other chemotherapeutic drugs and encouraging results have been obtained. Its prominent role is greatly enhanced in relapsed or refractory CD20 positive B-cell lymphoma remission rate and survival